Clinical Effect of Shenqiong Glucose on Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Heart Disease
ZHENG Yuqiang
SONG Zhucui
WANG Ning
CUI Chaobo
Abstract：Objective To investigate the clinical effect of combined therapy with Shenqiong glucose on chronic ob-structive pulmonary disease(COPD)complicated with pulmonary heart disease(PHD).Methods A total of 228 patients with COPD complicated with PHD were selected from January 2022 to January 2024 and randomly divided into observation group(n=114)and control group(n=114)by random number table method.The observation group was given Shenqiong glucose combined with conventional treatment,and the control group was given conventional treatment.Blood routine(erythro-cyte,erythrohemoglobin,hematocrit,platelet count),coagulation indexes[D-dimer(D-D),prothrombin time(PT),activa-ted partial thromplastin time(APTT),fibrinogen(FIB)],liver and kidney function[blood urea nitrogen(BUN),serum creatinine(Scr),alanine aminotransferase(ALT),aspartate aminotransferase(AST),total protein(TP)],blood gas inde-xes[arterial partial pressure of oxygen(PaO2),arterial partial pressure of carbon dioxide(PaCO2),arterial oxygen satura-tion(SaO2)],heart-type fatty acid-binding protein(H-FABP),cardiac troponin I(cTnI),N-terminal pro-B-type natriuretic peptide precursor(NT-proBNP),pulmonary artery systolic pressure(PASP),Acute Physiology And Chronic Health Evalua-tion Ⅱ(APACHE Ⅱ)scores were compared between the two groups.Additionally,28-day mortality after admission and ad-verse reactions during treatment were recorded.Results After treatment,erythrocyte,hemoglobin,hematocrit,platelet count,D-D,FIB,PaCO2,H-FABP,cTnI,NT-proBNP,PASP,APACHE Ⅱ in the two groups were lower than those before treatment,and lower in the observation group than in the control group.PT,APTT,PaO2 and SaO2 in the two groups were higher than those before treatment,and higher in the observation group than in the control group(P<0.05,P<0.01).Be-fore and after treatment,there were no significant differences in BUN,Scr,AST,ALT and TP between and within the two groups(P>0.05).There was no significant difference in 28-day mortality rate and the incidence of adverse reactions during treatment between the observation group[7.02％,8/114;7.89％,9/114]and control group(10.53％,12/114;5.26％,6/114)(P>0.05).Conclusion Shenqiong glucose can improve blood routine,coagulation indexes and blood gas indexes in COPD patients with PHD,and reduce the levels of H-FABP,cTnI and NT-proBNP,so as to reduce the degree of myocardi-al injury and alleviate the disease of patients.
Keywords：Pulmonary diseasechronic obstructiveComplicationsPulmonary heart diseaseShenqiong glucoseRed blood cellActivated partial thromboplastin timeAlanine transaminaseHeart-type fatty acid binding protein
Publication Date：2024-06-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：7( 88-94 )